Breast cancer recurrent risk assessment 21 gene detection primer and application thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of risk assessment and genetic detection, which is applied in the determination/inspection of microorganisms, biochemical equipment and methods, DNA/RNA fragments, etc., can solve the problems of high recurrence and transfer rates, shorten the time of detection experiments, improve efficiency, expand conditionally consistent effect
Inactive Publication Date: 2017-08-18
温州迪安医学检验所有限公司 +1
View PDF4 Cites 13 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
In recent years, the incidence rate in my country has been increasing year by year. Although clinical research has made great progress, the recurrence and metastasis rates are still high.
In the past 20 years, the multidisciplinary comprehensive treatment model centered on surgery and assisted by chemotherapy, radiotherapy, and endocrine therapy has been greatly developed, which has significantly reduced the recurrence and mortality of breast cancer, but there is still a lack of effective methods to accurately predict breast cancer. The patient's risk of recurrence and treatment accordingly
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0050] Example 1: Detecting the nucleic acid sequences of the 21 genes detected in breast cancer recurrence risk assessment.
[0051] 21 pairs of specific primers were entrusted to Yingwei Jieji (Shanghai) Trading Co., Ltd. to synthesize:
[0052] SEQ ID NO: 1 5'-CGGACTTTGGGTGCGACTT-3'
[0053] SEQ ID NO: 2 5'-TTACAACTCTTCCACTGGGACGAT-3'
[0054] SEQ ID NO: 3 5'-GCTAGAGGCATCATGGACCGA-3'
[0055] SEQ ID NO: 4 5'-GAAGGACACAAGACCCGCTGA-3'
[0056] SEQ ID NO: 5 5'-AGAACTGGCCCTTCTTGGAGG-3'
[0057] SEQ ID NO: 6 5'-TCTATGGGGTCGTCATCTGGC-3'
[0058] SEQ ID NO: 7 5'-TTCAGGTTGTTGCAGGAGAC-3'
[0059] SEQ ID NO: 8 5'-CATCTTCTTGGGCACACAAT-3'
[0060] SEQ ID NO: 9 5'-GCCGAGATCGCCAAGATG-3'
[0061] SEQ ID NO: 10 5'-CTTTTGATGGTAGAGTTCCAGTGATTC-3'
[0062] SEQ ID NO: 11 5'-CCATCTGCATCCATCTTGTT-3'
[0063] SEQ ID NO: 12 5'-GGCCACCAGGGTATTATCTG-3'
[0064] SEQ ID NO: 13 5'-CGGTGTGAGAAGTGCAGCAA-3'
[0065] SEQ ID NO: 14 5'-CCTCTCGCAAGTGCTCCAT-3'
[0066] SEQ ID NO: 15 5'-TGTCCAGCCACC...
Embodiment 2
[0094] Example 2: 21-gene detection method for breast cancer recurrence risk assessment.
[0097] Paraffin tissue RNA was extracted according to the instructions of the paraffin tissue RNA extraction kit produced by Qiagen Biological Company, and tissue RNA was obtained for future use.
[0098] (2) reverse transcription, the reagents were purchased from THERMO company
[0099] The reaction system is a 20 μL system, including 11 μL template RNA, 1 μL RT enzyme, 1 μL RI enzyme, 2 μL dNTP, 4 μL 5×buffer, and 1 μL random primer; reaction conditions: 42°C for 30 min, 95°C for 5 min.
[0100] Prepare 3 tubes for one specimen.
[0101] (3) Fluorescent quantitative PCR, the reagents were pu...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to a breast cancer recurrent risk assessment 21 gene detection primer and application thereof. The breast cancer recurrent risk assessment 21 gene detection primer comprises a nucleotide sequence as shown in an SEQ ID NO.: 1 to 42, and belongs to the technical field of molecular detection. The detection primer provided by the invention utilizes the advantage of fluorescent quantitation, and adopts fluorescent quantitation polymerase chain reaction to carry out amplification detection on 21 genes for breast cancer recurrent risk assessment, so that whether clinical measurements such as adjuvant chemotherapy are needed or not is considered. A kit provides a PCR (Polymerase Chain Reaction) amplification primer sequence of the 21 genes for breast cancer recurrent risk assessment, and the primer is applicable to detecting ER positive patients, HER2 negative patients, axillary node negative patients, moderately and poorly differentiated patients with the tumor size being 0.6 to 1.0cm and adverse prognostic factors, or patients with the tumor size is larger than 1cm, has the advantages of high sensitivity and specificity, stability, promptness, convenience in operation and the like, can well meet the clinical application of breast cancer recurrent risk assessment, and can be beneficial for reducing invalid medication administration, improving medication administration accuracy, and reducing financial burdens of the patients.
Description
technical field [0001] The invention belongs to the technical field of molecular detection, and in particular relates to a detection kit specially used for the nucleic acid sequence of breast cancer recurrence risk assessment 21 gene. Background technique [0002] Breast cancer is a major malignant tumor that endangers women's health. About 1.2 million women worldwide suffer from breast cancer every year, and 500,000 people die from breast cancer. The average mortality rate of breast cancer in my country is 2.61 / 100,000, and the mortality rate in several coastal cities is significantly higher, and the mortality rate in cities is 1.4 times higher than that in rural areas. In recent years, the incidence rate in my country has been increasing year by year. Although clinical research has made great progress, the recurrence and metastasis rates are still high. In the past 20 years, the multidisciplinary comprehensive treatment model centered on surgery and assisted by chemothera...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more